The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics’ first patient dosing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results